
LifeMD (LFMD) Stock Forecast & Price Target
LifeMD (LFMD) Analyst Ratings
Bulls say
LifeMD Inc. demonstrated strong financial performance in the latest quarter, with its active telehealth subscriber base growing by 16% year-over-year to approximately 323,000 by the end of 4Q25, and with a substantial increase of 13,000 net new subscribers added in that quarter alone. The company reported total revenue of $60.2 million, achieving a 12.7% year-over-year growth, while telehealth-specific revenue rose by 17.4% to $47.3 million, showcasing the continued demand for its healthcare services. Additionally, LifeMD benefited from an impressive gross margin expansion to 87%, reflecting a favorable revenue mix and an established foothold in the growing telehealth market.
Bears say
LifeMD Inc. faces significant challenges that may negatively impact its stock outlook, including an inability to meet growth projections for telehealth revenue, as demonstrated by a disappointing quarterly revenue of $60.2 million, which fell short of expectations. The company also reduced its full-year 2025 revenue guidance to $192 million - $193 million following a decline in revenue from its WorkSimplifi segment, suggesting a slowdown in overall business growth. Additionally, numerous risks, such as competition, patient acquisition and retention difficulties, and potential dilution, further exacerbate concerns regarding the company's path to profitability.
This aggregate rating is based on analysts' research of LifeMD and is not a guaranteed prediction by Public.com or investment advice.
LifeMD (LFMD) Analyst Forecast & Price Prediction
Start investing in LifeMD (LFMD)
Order type
Buy in
Order amount
Est. shares
0 shares